Your partner in oncology

oncology therapeUtic development

 A CRO focused solely on oncology, specialized in the early development of single agent and combination anticancer regimens.

  • Ensure rapid and efficient development of promising new cancer treatments
  • Offer preclinical and clinical consulting for VC groups or mid-size biotech companies
  • Optimize, launch and execute your clinical development plan
  • Support companies by providing strong medical input and oncology-experienced staff
  • Are a key partner working with small and mid-size companies
  • Can design preclinical models to guide clinical development
  • Perform clinical Phase I/II study design and implementation


Our goal is to support our partners to establish a clinical development plan to generate data in a timely, efficient and cost-effective manner.




BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.

 Oncotarget. 2015 May 14


OTD - Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us